Intravenous administration of enprofylline to asthmatic patients
- 1 January 1983
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 24 (3) , 323-327
- https://doi.org/10.1007/bf00610048
Abstract
In 6 asthmatic patients, the possibility of obtaining a steady state plasma level of 5 mg/l of enprofylline by administration of two constant rate infusions was examined. The simulated plasma concentration curves, based on information from pressessment of individual pharmacokinetic parameters, were in good agreement with the plasma levels obtained. The side-effects and bronchodilatation produced by enprofylline were compared to those obtained with theophylline at a steady state level of 15 mg/l. Enprofylline and theophylline caused a mean maximal increase in FEV1.0 of 14% and 2.6% per mg/l in plasma, respectively. Side-effects, head-ache, nausea and vomiting, became pronounced in 2 patients in whom the plasma enprofylline level was about 6 mg/l. No other serious adverse reaction was seen. It is suggested that enprofylline should be further evaluated as a possible anti-asthmatic drug.This publication has 11 references indexed in Scilit:
- Enprofylline kinetics in healthy subjects after single dosesClinical Pharmacology & Therapeutics, 1983
- Enprofylline - Effects of a New Bronchodilating Xanthine Derivative in Asthmatic PatientsAllergy, 1983
- Effects of enprofylline, a xanthine lacking adenosine receptor antagonism, in patients with chronic obstructive lung diseaseEuropean Journal of Clinical Pharmacology, 1982
- Adenosine Antagonism, a Less Desirable Characteristic of Xanthine Asthma Drugs?Acta Pharmacologica et Toxicologica, 1981
- Enprofylline, a Principally New Antiasthmatic XanthineActa Pharmacologica et Toxicologica, 1981
- Noncompartmental Determination of the Steady‐State Volume of DistributionJournal of Pharmaceutical Sciences, 1979
- Clinical Toxicity of Theophylline in Relation to Cigarette SmokingChest, 1978
- A safe method for rapidly achieving plasma concentration plateausClinical Pharmacology & Therapeutics, 1974